Systematic review and subgroup analysis of the incidence of acute kidney injury (AKI) in patients with COVID-19
Abstract Background Acute kidney injury (AKI) occurs among patients with coronavirus disease-19 (COVID-19) and has also been indicated to be associated with in-hospital mortality. Remdesivir has been authorized for the treatment of COVID-19. We conducted a systematic review to evaluate the incidence...
Main Authors: | Zhenjian Xu, Ying Tang, Qiuyan Huang, Sha Fu, Xiaomei Li, Baojuan Lin, Anping Xu, Junzhe Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-02-01
|
Series: | BMC Nephrology |
Online Access: | https://doi.org/10.1186/s12882-021-02244-x |
Similar Items
-
Effects of Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction in Patients Undergoing Peritoneal Dialysis
by: Sha Fu, et al.
Published: (2021-06-01) -
The incidence, risk factors, and long-term outcomes of acute kidney injury in hospitalized diabetic ketoacidosis patients
by: Junzhe Chen, et al.
Published: (2020-02-01) -
Incidence and In‐Hospital Mortality of Acute Kidney Injury (AKI) and Dialysis‐Requiring AKI (AKI‐D) After Cardiac Catheterization in the National Inpatient Sample
by: Jeremiah R. Brown, et al.
Published: (2016-03-01) -
Biomarker Acute Kidney Injury (AKI) pada Sepsis
by: Dional Setiawan, et al.
Published: (2018-07-01) -
Cell-Based Therapies in Acute Kidney Injury (AKI)
by: Daniel Patschan, et al.
Published: (2018-05-01)